-
1 Comment
SMS Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 40.6% above its 200 day moving average.
From a valuation standpoint, the stock is 54.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
SMS Pharmaceuticals Limited's total revenue rose by 85.0% to $1B since the same quarter in the previous year.
Its net income has increased by 180.9% to $214M since the same quarter in the previous year.
Finally, its free cash flow grew by 32.3% to $349M since the same quarter in the previous year.
Based on the above factors, SMS Pharmaceuticals Limited gets an overall score of 5/5.
Exchange | NSE |
---|---|
CurrencyCode | INR |
ISIN | INE812G01025 |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Dividend Yield | 0.2% |
---|---|
Market Cap | 21B |
Beta | 1.23 |
PE Ratio | 30.74 |
Target Price | None |
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. The company offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SMSPHARMA.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025